{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:51:19Z","timestamp":1777434679672,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.afos.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:06:22Z","timestamp":1552521982000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2396-5951","authenticated-orcid":false,"given":"Junko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-9980","authenticated-orcid":false,"given":"Hiroyuki","family":"Kakihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-8811","authenticated-orcid":false,"given":"Yousuke","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-2027","authenticated-orcid":false,"given":"Michiko","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-8800","authenticated-orcid":false,"given":"Chiemi","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.afos.2019.02.002_bib2","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.afos.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","article-title":"Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","article-title":"Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension","volume":"23","author":"Bianchi","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","article-title":"Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies","volume":"24","author":"Harris","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.afos.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","article-title":"Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data","volume":"20","author":"Cranney","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-013-2518-z","article-title":"Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies","volume":"25","author":"Miller","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib8","first-page":"197","article-title":"Innovation of bisphosphonates for improvement of adherence","volume":"27","author":"Takeuchi","year":"2017","journal-title":"Clin Calcium"},{"key":"10.1016\/j.afos.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00223-014-9927-7","article-title":"Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study","volume":"95","author":"Hagino","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00774-015-0723-x","article-title":"Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study","volume":"35","author":"Ito","year":"2017","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2019.02.002_bib12","first-page":"47","article-title":"Effects of ibandronate with eldecalcitol treatment on bone mineral density and the structural geometry of the proximal femur in Japanese women with osteoporosis","volume":"3","author":"Takada","year":"2017","journal-title":"J\u00a0Japan Osteoporos Soc"},{"key":"10.1016\/j.afos.2019.02.002_bib13","first-page":"1085","article-title":"Additional use of vitamin D and intravenous ibandronate could be a solution of insufficient effect of solitary use of oral bisphosphonates or SERM for osteoporosis patients in Japan","volume":"37","author":"Kishikawa","year":"2016","journal-title":"Ther Res"},{"key":"10.1016\/j.afos.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.afos.2018.01.001","article-title":"Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis","volume":"4","author":"Takeuchi","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.afos.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","article-title":"Diagnostic criteria for primary osteoporosis: year 2000 revision","volume":"19","author":"Orimo","year":"2001","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00198-015-3175-1","article-title":"Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis","volume":"26","author":"Nakamura","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00774-017-0839-2","article-title":"Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study","volume":"36","author":"Hagino","year":"2018","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00198-015-3049-6","article-title":"Erratum to: efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis","volume":"26","author":"Sakai","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","article-title":"A\u00a0new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study","volume":"49","author":"Matsumoto","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.afos.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","article-title":"Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis","volume":"44","author":"Sebba","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.afos.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00223-010-9403-y","article-title":"Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate","volume":"87","author":"Miller","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525519300019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525519300019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T07:44:10Z","timestamp":1565163850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525519300019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2405525519300019"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2019.02.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}